Management of transitional cell carcinoma.

Area of Science:

• Veterinary Oncology
• Canine Cancer Research
• Urological Pathology

Background:

• Canine transitional cell carcinoma (TCC) of the bladder is locally invasive and prone to metastasis.
• Early detection and multimodality therapy are key for favorable outcomes in canine bladder cancer.
• Current median survival times for canine TCC do not exceed one year, irrespective of treatment.

Purpose of the Study:

• Investigate urine screening tests for earlier detection of canine TCC.
• Evaluate current therapeutic strategies for canine bladder cancer.
• Identify potential improvements in canine TCC treatment and patient survival.

Main Methods:

• Review of current diagnostic and therapeutic approaches for canine TCC.
• Assessment of the potential of urine-based screening tests for early detection.
• Analysis of treatment outcomes, including chemotherapy, piroxicam, surgery, and radiation therapy.

Main Results:

• Urine screening tests are under investigation for earlier canine TCC detection.
• Combination protocols with chemotherapy and piroxicam show promise for tumor response.
• Surgery and radiation therapy are beneficial in specific canine TCC cases.
• Tumor seeding risk must be considered during urine collection and surgery.

Conclusions:

• Accurate early detection tests for canine TCC could significantly improve treatment success.
• Multimodality therapy offers the best approach, but cures remain unlikely due to invasiveness and metastasis.
• Ongoing research focuses on improving diagnostic accuracy and therapeutic efficacy for canine bladder cancer.